Zika Vaccine Makers, 21st Century Cures Task Force Hit By Regulatory Freeze
Executive Summary
HHS asked Federal Register Office to withdraw declaration providing liability immunity to Zika vaccine manufacturers and notice delegating authority under the Cures Act to refine the clinical trials data registry.
You may also be interested in...
US FDA Clarifies ‘Intended Use’ Policy For Approved Products
‘Totality of evidence’ establishes that a manufacturer intends a drug to be used for unapproved conditions, agency says; PhRMA says final rule disregards multiple courts’ protection of free speech.
HHS Shields Three Ebola Vaccine Makers From Legal Liability
GlaxoSmithKline, NewLink Genetics and Johnson & Johnson gain protection for their candidate Ebola vaccines; NewLink teams up with Merck, and GSK prepares for Phase II/III studies in West Africa.
Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: